Teva Pharmaceutical Industries Ltd. — Earnings Release 2004

Oct 24, 2004

==> picture [120 x 39] intentionally omitted <==

Teva Pharmaceutical Industries Ltd. Web Site: www.tevapharm.com

Contact: Dan Suesskind Chief Financial Officer Teva Pharmaceutical Industries Ltd. (011) 972-2-589-2840 Bill Fletcher President and CEO Teva North America FOR IMMEDIATE RELEASE (215) 591-8800 Dorit Meltzer Director, Investor Relations Teva Pharmaceutical Industries Ltd. (011) 972-3-926-7554

TEVA ANNOUNCES THIRD QUARTER GLOBAL IN-MARKET SALES OF COPAXONE INCREASED 34% TO $242 MILLION

Jerusalem, Israel, October 21, 2004 – Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) announced today, in conjunction with the release of its partner Sanofi-Aventis Group’s financial results, that global in-market sales of Copaxone® amounted to $242 million in the third quarter ended September 30[th] , an increase of 34% over the comparable quarter of 2003.

U.S. sales increased 32% over the third quarter of 2003 to $163 million. Sales outside the U.S, mainly in Europe, increased by 39%, to $79 million.

During the first nine month period of 2004, global in-market sales of Copaxone® totaled $675 million, an increase of 32% over the comparable period of 2003. U.S. in-market sales increased 28% to $450 million and non US in-market sales increased 41% to $224 million.

In the U.S., the world’s largest MS market, Copaxone’s total prescription share continued to build on the 30% milestone achieved in June, capturing 30.5% of the market’s total prescriptions in the third quarter of 2004.

As previously announced, Teva will release its Third Quarter 2004 financial results two weeks from today on Thursday, November 4, 2004.

Teva Pharmaceutical Industries Ltd., headquartered in Israel, is among the top 25 pharmaceutical companies and among the largest generic pharmaceutical companies in the world. The company develops, manufactures and markets generic and innovative human pharmaceuticals and active pharmaceutical ingredients. Close to 90% of Teva’s sales are in North America and Europe.

Safe Harbor Statement under the U. S. Private Securities Litigation Reform Act of 1995: This release contains forward-looking statements, which express the current beliefs and expectations of management. Such statements are based on current expectations and involve a number of known and unknown risks and uncertainties that could cause Teva's future results, performance or achievements to differ significantly from the results, performance or achievements expressed or implied by such forward-looking statements. Important factors that could cause or contribute to such differences include Teva's ability to successfully develop and commercialize additional pharmaceutical products, the introduction of competitive generic products, the impact of competition from brand-name companies that sell their own generic products or successfully extend the exclusivity period of their branded products, Teva's ability to rapidly integrate the operations of acquired businesses, including its recent acquisition of Sicor Inc., the availability of product liability coverage in the current insurance market, the impact of pharmaceutical industry regulation and pending legislation that could affect the pharmaceutical industry, the difficulty of predicting U.S. Food and Drug Administration and other regulatory authority approvals, the regulatory environment and changes in the health policies and structure of various countries, acceptance and demand for new pharmaceutical products and new therapies, uncertainties regarding market acceptance of innovative products newly launched, currently being sold or in development, the impact of restructuring of clients, reliance on strategic alliances, exposure to product liability claims, dependence on patent and other protections for innovative products, fluctuations in currency, exchange and interest rates, operating results and other factors that are discussed in Teva's Annual Report on Form 20-F and its other filings with the U.S. Securities and Exchange Commission. Forward-looking statements speak only as of the date on which they are made, and the Company undertakes no obligation to update publicly or revise any forward-looking statement, whether as a result of new information, future developments or otherwise.

"מ ע תעשיות פרמצבטיות בעטב

==> picture [108 x 41] intentionally omitted <==

----- Start of picture text ----- A----- End of picture text -----

, 2004אוקטובר ב21

® עלו , לרבעון השלישי, במונחי מכירה לשוק ופקסוןקשל הגלובליות ה טבע מודיעה כי המכירות 242 מליון$ 34% והסתכמו ב- ב-

כי המכירות ,Sanofi-Aventis, טבע פרסום התוצאות הכספיות של שותפתה שלל בהמשך ,ודיעה היוםה טבע גידול של ,$ מליון242, ב- ברבעון השלישי של 2004הסתכמו,[®] קופקסון של , במונחי מכירה לשוקהגלובליות . לעומת הרבעון המקביל בשנת200334%

ץ המכירות מחו ו 163 מליון$ של 2003 והסתכמו ב- לעומת הרבעון השלישי 32%ב גדלו ב-"המכירות בארה . 79 מליון$ והסתכמו ב- 39%ב עלו-, בעיקר באירופה"ב,לארה לעומת גידול של32% ,$ 675 מליון ,הסתכמו ב-תשעת החודשים הראשונים של 2004 ב[®] מכירות הקופקסון המכירות ו 450 מליון$ 28% והסתכמו ב- ב - עלו, בתקופה זו "ב המכירות בארה .אשתקדהתקופה המקבילה מליון$. 22441% והסתכמו ב- לו ב- ב גד"מחוץ לארה , בעולם ביותרשוק הטרשת הנפוצה הגדול, ב"בארה, סך כל המרשמיםשל במונחים ,[®] נתח השוק של קופקסון נתח השוק של הגיע, ברבעון השלישי של2004 . 2004 יוני ב שהושג דרךה ציון, 30%ל- עבר מ המשיך לגדול ® . שוקם במרשמיה מסך כל30.5% ל- קופקסון יום , בשנת 2004 בעוד שבועייםשל שלישי הלרבעון כספיותהתפרסם את תוצאותיה החברה, שהודיעה טבעכפי . , 2004, 4 בנובמברחמישי החברות הפרמצבטיות 25מ הינה חברה גלובלית שבסיסה בישראל ואחת מ- "טבע תעשיות פרמצבטיות בע תרופות גנריות וייחודיות ובייצור חומרים פעילים לתעשיה המתמחה בייצור , טבע. המובילות בעולם , שיווק והפצה בישראל, מחקר, לטבע אתרי ייצור. הינה אחת מהמובילות בעולם בתחום הגנריקה, הפרמצבטית . 90% ממכירותיה של הקבוצה הן לצפון אמריקה ואירופהקרוב ל- . אמריקה ובאירופהומרכז בצפון

---------------

ב בשם "להלן הסעיף הידוע בארה"Safe Harbor" ואשר מטרתו להגן על החברהבכל הקשור לנתונים שיש להם משמעות , י הדין האמריקאי" עפ , :של תחזית ואשר כתוצאה מכך חשופים לסיכונים ואי ודאות Safe Harbor Statement under the U. S. Private Securities Litigation Reform Act of 1995: This release contains forward-looking statements, which express the current beliefs and expectations of management. Such statements are based on current expectations and involve a number of known and unknown risks and uncertainties that could cause Teva’s future results, performance or achievements to differ significantly from the results, performance or achievements expressed or implied by such forwardlooking statements. Important factors that could cause or contribute to such differences include Teva’s ability to successfully develop and commercialize additional pharmaceutical products, the introduction of competitive generic products, the impact of competition from brand-name companies that sell their own generic products or successfully extend the exclusivity period of their branded products, Teva’s ability to rapidly integrate the operations of acquired businesses, including its recent acquisition of Sicor Inc., the availability of product liability coverage in the current insurance market, the impact of pharmaceutical industry regulation and pending legislation that could affect the pharmaceutical industry, the difficulty of predicting U.S. Food and Drug Administration and other regulatory authority approvals, the regulatory environment and changes in the health policies and structure of various countries, acceptance and demand for new pharmaceutical products and new therapies, uncertainties regarding market acceptance of innovative products newly launched, currently being sold or in development, the impact of restructuring of clients, reliance on strategic alliances, exposure to product liability claims, dependence on patent and other protections for innovative products, fluctuations in currency, exchange and interest rates, operating results and other factors that are discussed in Teva's Annual Report on Form 20-F and its other filings with the U.S. Securities and Exchange Commission. Forward-looking statements speak only as of the date on which they are made, and the Company undertakes no obligation to update publicly or revise any forward-looking statement, whether as a result of new information, future developments or otherwise.

dorit.meltzer@teva.coil. מנהלת קשרי משקיעים – דורית מלצר 03-9267519 פקסימיליה 03-9267554 . תקוה49131 טלבזל 5ד . ת3190 פתח-' רח

Web site: www.tevapharm.com